Xgene Pharmaceutical Overview
- Year Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$36.9M
- Investors
-
13
Xgene Pharmaceutical General Information
Description
Developer of innovative multimodal conjugated molecules designed to transform the treatment landscape of neurological disorders. The company's platform utilizes proprietary linker technology to generate dual-acting conjugates that combine therapeutic molecules, providing patients with non-opioid analgesic treatments that offer improved efficacy and reduced toxicity for neuropathic and nociceptive pain.
Contact Information
Website
www.xgenepharm.comCorporate Office
- 9F-13
- No.188, Sec. 5, Nanjing E. Road, Shungshan Dist.
- Taipei, 105
- Taiwan
Corporate Office
- 9F-13
- No.188, Sec. 5, Nanjing E. Road, Shungshan Dist.
- Taipei, 105
- Taiwan
Xgene Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series D) | 28-Jul-2026 | $36.9M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series C) | 04-Nov-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B1) | 04-May-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 23-Oct-2018 | $20M | $20M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Mar-2016 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Xgene Pharmaceutical Patents
Xgene Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026194901-A1 | Naproxen/pregabalin conjugate tablet formulation | Pending | 18-Mar-2025 | ||
| WO-2026035552-A1 | Naproxen/pregabalin conjugate dosing regimen | Pending | 05-Aug-2024 | ||
| AU-2025276373-A1 | Method of treating pain using topical naproxen and pregabalin conjugate formulations | Pending | 29-May-2024 | ||
| WO-2025250613-A1 | Method of treating pain using topical naproxen and pregabalin conjugate formulations | Pending | 29-May-2024 | ||
| WO-2025064492-A1 | Trpm8 antagonist for treating cancer | Inactive | 19-Sep-2023 | A61K31/501 |
Xgene Pharmaceutical Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shenzhen GTJA Investment Group | Venture Capital | Minority | ||
| Shenzhen Yifeng Investment Management Enterprise | Venture Capital | Minority | ||
| CITIC Securities | Investment Bank | Minority | ||
| Daoyuan Capital | Venture Capital | Minority | ||
| GSR United Capital | Growth/Expansion | Minority |
Xgene Pharmaceutical FAQs
-
When was Xgene Pharmaceutical founded?
Xgene Pharmaceutical was founded in 2015.
-
Where is Xgene Pharmaceutical headquartered?
Xgene Pharmaceutical is headquartered in Taipei, Taiwan.
-
What industry is Xgene Pharmaceutical in?
Xgene Pharmaceutical’s primary industry is Drug Discovery.
-
Is Xgene Pharmaceutical a private or public company?
Xgene Pharmaceutical is a Private company.
-
What is Xgene Pharmaceutical’s current revenue?
The current revenue for Xgene Pharmaceutical is .
-
How much funding has Xgene Pharmaceutical raised over time?
Xgene Pharmaceutical has raised $96.9M.
-
Who are Xgene Pharmaceutical’s investors?
Shenzhen GTJA Investment Group, Shenzhen Yifeng Investment Management Enterprise, CITIC Securities, Daoyuan Capital, and GSR United Capital are 5 of 13 investors who have invested in Xgene Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process